Almac’s Sciences Business Unit will manufacture the production of MGB Biopharma‘s lead gram positive antibacterial compound MGB-BP3. The compound is a DNA minor groove binder and is currently in preclinical development, with IND filing targeted for Q3 2012. MGB Bio’s chief executive officer, Dr. Miroslav Ravic, commented, “We were very quickly impressed with the approach taken by Almac and they have already shown an intuitive understanding of what it takes to support a small company...